AML On The Go - Selective Inhibition of FLT3 by Gilteritinib 

Selective Inhibition of FLT3 by Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia: A Multicenter, First-in-human, Open Label, Phase 1-2 Study - pub. 11/14/17
AMLOTG21